2 completed, 1 terminated, 1 withdrawn. 3 Phase 2, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 4 | 1 | Completed 1 |
Follow arginyllysine: new trials by email Literature Review of arginyllysine trials Research Report on arginyllysine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients arginine/lysine - Gastroenteropancreatic Neuroendocrine Tumors | Phase 4 | Completed | Advanced Accelerator Applications | 42 | 2021-01-25 | 2025-01-24 |
| Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) 90Y-DOTA tyr3-Octreotide, 68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan, Amino Acids - Neuroendocrine Tumors, Meningioma | Phase 2 | Completed | University of Iowa | 39 | 2017-09-29 | 2023-02-09 |
| Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs Satoreotide tetraxetan, Amino acid solution, Antiemetic - Neuroendocrine Tumors | Phase 1 / Phase 2 | Terminated | Ipsen | 40 | 2017-03-06 | 2023-07-19 |
| Dosimetry Guided PRRT With 90Y-DOTATOC 90Y-DOTA-3-tyr-Octreotide, Positron Emission Tomography (PET) whole body scan, Amino Acids - Neuroendrocrine Tumors, Meningioma | Phase 2 | Withdrawn | Sue O'Dorisio | 2017-01-01 | 2017-08-25 |
Neuroendocrine Tumors (3) · Medulloblastoma (2) · Meningioma (2) · Neuroblastoma (2) · Carcinoid Tumor (1) · Gastro-enteropancreatic neuroendocrine tumor (1)
Advanced Accelerator Applications (1) · Ipsen (1) · Sue O'Dorisio (1) · University of Iowa (1)
United Kingdom (2) · United States (2) · Australia (1) · Austria (1) · Canada (1) · Denmark (1) · France (1) · Italy (1) · Netherlands (1) · Poland (1) · Switzerland (1)
M S O'Dorisio, MD, PhD (1) · M. Sue O'Dorisio, MD, PhD (1)
R01CA167632 (2), 2015 (1), 2019 (1)